

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Tryptamine Therapeutics Limited
ABN	78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Gage Jull
Date of last notice	6 May 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder)	N/A
Date of change	(1) N/A (2) N/A (3) N/A (4) 02 December 2024
No. of securities held prior to change	(1) 258,287 ORDINARY FULLY PAID SHARES (2) 1,418,918 ORDINARY FULLY PAID SHARES - ESCROWED 24 MONTH FROM QUOTATION (3) 10,124,800 - UNLISTED OPTIONS @ \$0.0531 EXP 5Y REINST 24M ESC (4) NIL - Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027
Class	(1) ORDINARY FULLY PAID SHARES (2) ORDINARY FULLY PAID SHARES - ESCROWED 24 MONTH FROM QUOTATION (3) UNLISTED OPTIONS @ \$0.0531 EXP 5Y REINST 24M ESC (4) Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027

⁺ See [chapter 19](#) for defined terms.

Number acquired	(1) NIL (2) NIL (3) NIL (4) 1,000,000 - Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027
Number disposed	N/A
Value/Consideration	(1) N/A (2) N/A (3) N/A (4) NIL
No. of securities held after change	(1) 258,287 ORDINARY FULLY PAID SHARES (2) 1,418,918 ORDINARY FULLY PAID SHARES - ESCROWED 24 MONTH FROM QUOTATION (3) 10,124,800 - UNLISTED OPTIONS @ \$0.0531 EXP 5Y REINST 24M ESC (4) 1,000,000 - Dir AGM24 Opt \$0.03 Vest 31/12/2024 Exp 31/12/2027
Nature of change	(1) N/A (2) N/A (3) N/A (4) ALLOTMENT OF DIRECTOR OPTIONS AS APPROVED BY SHAREHOLDERS ON 8 NOVEMBER 2024

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

⁺ See [chapter 19](#) for defined terms.

Were the interests in the securities or contracts detailed above traded during a closed period where prior written clearance was required?	NO
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A